Finanzen von Crescent Biopharma, Inc. (CBIO)CBIOCrescent Biopharma, Inc.

Evaluating the bottom line, Crescent Biopharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4917.52%, while the net margin is -4631.38%. These profitability ratios, combined with a Return on Equity (ROE) of -113.49%, provide a clear picture of how effectively CBIO converts its operational activities into shareholder value.

In the context of the broader market, CBIO competes directly with industry leaders such as PRTA and ALT. With a market capitalization of $489.19M, it holds a leading position in the sector. When comparing efficiency, CBIO's gross margin of 100.00% stands against PRTA's 100.00% and ALT's N/A. Such benchmarking helps identify whether Crescent Biopharma, Inc. is trading at a premium or discount relative to its financial performance.

Crescent Biopharma has reported a gross margin of 100% for Q4 2025, indicating strong potential profitability once revenue starts flowing. However, the company has been experiencing significant net losses, with a net income of -$24.8 million in Q2 2026.